Corcept Therapeutics Inc

Insider buying by Corcept Therapeutics’ owner signals confidence despite FDA and legal headwinds, offering investors a stabilizing signal amid market volatility.

Corcept Therapeutics insiders buy 1.18 M options, boosting confidence amid a 41% share decline and pending fraud lawsuit.

Corcept insider trades reveal strategic confidence amid earnings miss – James Wilson buys at $3.88, sells at $36.48, signalling liquidity strategy and voting power consolidation for future option exercises and long‑term growth.